The global pharma giant cut more than 400 jobs in the state last year, after investing at least $360 million in its local manufacturing operations.
Stocktwits on MSN
Sarepta hits fresh hurdle as court revives patent lawsuit with Regenxbio over muscular disorder therapy
Regenxbio filed a lawsuit in 2020 alleging that Elevidys infringed a gene-therapy patent that the company licenses from ...
Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. | Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This ...
Biotech company Regenxbio and the University of Pennsylvania on Friday convinced a U.S. appeals court to revive their patent lawsuit against Sarepta Therapeutics over Sarepta's Duchenne muscular ...
Japan’s Chugai today announced that it launched Elevidys intravenous infusion (delandistrogene moxeparvovec), which received ...
Lasting gains in swallowing ability have been reported for four people with oculopharyngeal muscular dystrophy given gene therapy in a trial.
Zacks Investment Research on MSN
Should investors buy, sell or hold KROS stock ahead of Q4 earnings?
We expect investors to focus on pipeline updates when Keros Therapeutics KROS reports fourth-quarter results shortly. The Zacks Consensus Estimate for sales and loss per share is pegged at $6.50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results